Ueda2015 type 2 dm burden consequences_dr.mohamed mashahit

23
Type- 2 Diabetes , Burden & consequences

Transcript of Ueda2015 type 2 dm burden consequences_dr.mohamed mashahit

Type- 2 Diabetes , Burden & consequences

Type 2 diabetes is a major healthcare burden

Diabetes is a huge and growing problem, and the costs to society are high and escalating

International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas

Economic Costs of Diabetes

International Diabetes Federation. Diabetes Atlas. 4th ed. http://atlas.idf-bxl.org/sites/default/files/Economic%20impact%20of%20Diabetes.pdf

214

105

38

8 6 3 10

50

100

150

200

250

AFRMENA SEASACAEUR WPNAC

US

Do

llars

(m

illio

ns)

Diabetes Health Expenditures, 2010

558

303337

49

0

100

200

300

400

500

600

BrazilRussia IndiaChina

Inte

rnat

ion

al D

olla

rs (

bill

ion

s)

Predicted Net Losses in National Income From Diabetes and CVD,

2005-2015

Diabetes burden is not yet fully addressed…

175 million people with diabetes are undiagnosed

International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas

Prevalence* (%) estimates of diabetes (20-79 years), 2013

International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas

World Health Organisation, Regional Office for Eastern Mediterranean Region – Global Database on Body Mass Indexhttp://www.emro.who.int/nutrition/obesity_emr.htm Accessed December 2011

Obesity in MENA Region, 2010

Misunderstanding & low awareness of diabetes across the MENA Region

Country Population at risk (%)

Not aware of risk / not checked (%)

Knowledge of severity

Common misconceptions

ALGERIA 38 35 10% not sure what diabetes is

31% believe contagious

EGYPT 54 - >50 believe benign 63% believe caused by stressOnly 16% believe linked to diet

IRAN 21 80 97 believe benign -

IRAQ 44 - - 58% believe caused by stressOnly 5% believe linked to lack of exercise & diet

JORDAN 39 20 >50 believe benign -

LEBANON 45 50 - 43% believe caused by stressOnly 33% gave bad eating habits as cause

MOROCCO 41 15 >25% believe contagious

SAUDI ARABIA 52 45 50% believe benign -

TUNISIA 33 81 50% believe benign >50% believe caused by stress

UAE 42 90 - Only 21% believe caused by obesity

MENA Diabetes Leadership Forum 2010 Dubai Report Accessed December 2011http://www.novonordisk.com/images/about_us/changing-

diabetes/PDF/Leadership%20forum%20pdfs/MENA%20Forum/Diabetes%20in%20the%20Middle%20East%20and%20Northern%20Africa%20+%20DAS.pf

Diabetes Mortality by Region, 2010

International Diabetes Federation. Diabetes Atlas. 4th ed. http://atlas.idf-bxl.org/content/diabetes-mortality.

The Global Burden - Top 10 countries / territories of numberof people with diabetes (20-79 years), 2013

In Middle East Region

International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas

Top 10 countries/territories for number of people with diabetes (20-79 years), 2013 and 2035

7.5 13.1

International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas

T2DM trends in Egypt- Prevalence

11

35 - 44

45 - 54

55 - 65

25 - 34

0

5

10

Pre

vale

nce

(%

)

8.6

15

7.0

10.4

TotalMale Female

Age Categories

42.6 %

8.8 %

20.3 %

28.3 %

Egyptian Ministry of Health (MOH ) Preventive Sector, Central Epidemiology and Disease Surveillance (ESU) 2006

Mortality among diabetic and non-diabetic Egyptian patients with end-stage renal disease

Cause of mortality among diabetic and non-diabetic Egyptian patients with end-stagerenal disease

Eastern Mediterranean Health Journal, Vol. 10, Nos 4/5, 2004

Type 2 diabetes is already a major healthcare burden

4 million

The number of deaths annually from diabetes1

The average reduction in life expectancy of a person with type 2 diabetes1

5-10 years

US$58 billion

The economic burden of lost productivity due to type 2 diabetes in the USA alone2

1. World Heart Federation Fact Sheet on Diabetes and Cardiovascular Disease2. International Diabetes Federation. Diabetes Atlas, Fourth Edition. www.diabetesatlas.org (accessed 9 June 2011).

Every 10 seconds one person dies from diabetes related complications1

120 new patients will need dialysis

in the US*

230 new patients will have an

amputation in the US*

55 new patients will go blind due to

diabetesin the US*

In the next 24 hours…. 17,280 patients will develop diabetes

Heart disease by 2-4x*

Diabetes significantly increases risk of…

Stroketo more than 2-4x

the general population*

1 International Diabetes Federation. The diabetes epidemic: facts. www.worlddiabetesday.org/files/docs/Diabetes_facts.pdf.

*Adapted from : CDC 2011 National Diabetes Fact Sheet, http://www.cdc.gov/diabetes/pubs/estimates11.htm#12

Accessed June 2011

The Cardiovascular Risk associated with diabetes

0

20

40

60

80

100

120

140

None One only Two only All three

Non diabetic

DiabeticA

ge a

dju

sted

CV

D d

eat

h r

ate

per

1

0,0

00

pe

rso

n y

ears

Additional risk factors from cholesterol, hypertension and

smoking

CVD, cardiovasular disease Stamler et al. Diabetes Care 1993 16(2) 434-444

B Sobel et al., Circ 2003; 107:636 (CDC, PMD

-50

-40

-30

-20

-10

0

10

20

30

40

50Diabetes Mortality

Cancer Mortality

All-Cause Mortality

Major CVD Mortality

Year

% Change

in Age-

Adjusted

Mortality

Rate Since

1979

Change in Age-Adjusted Mortality Rates over time

1%

Lessons from Large Clinical Intervention Trials: Better Control Means Fewer Complications

Stratton IM, et al. BMJ. 2000;321:405-412.

*P<0.0001

Intensive Therapy Is Associated With a Lower Risk of Death From Cardiovascular Causes

Gaede P, et al. N Engl J Med. 2008;358:580-591.

20

40

60

80

0

0 2 4 6 8 10 12

Cu

mu

lati

ve In

cid

en

ce o

f A

ny

Car

dio

vasc

ula

r E

ven

t (%

)

YearsNo. at Risk

Conventional 80 70 60 46 38 29 25 14

Intensive 80 72 65 61 56 50 47 31

P<0.001

Conventional Treatment

Intensive Treatment

Intervention Follow-up

Time Course of Development of Diabetic Nephropathy

CKD=chronic kidney disease; GFR=glomerular filtration rate.

Adapted from DeFronzo RA. In Therapy for Diabetes Mellitus and Related Disorders, 3d ed. Alexandria, VA: American Diabetes Association; 1998.

Fauci AS, et al, eds. Chapter 338. Diabetes mellitus. In: Harrison’s Online. McGraw-Hill. www.accessmedicine.com. Accessed August 1, 2010.

Time from onset of diabetes, years 0 3 5 10 15 20 25

1201.0

1500.8

1500.8

1201.0

60>2.0

<10>5

GFR, mL/minSerum creatinine, mg/dL

CKD

No CKD/ Stage 1 Stage2

Stage3

Stage4-5

90 30

Microalbuminuria Gross proteinuria

Kidney Damage in Patients With T2DM Is Linked to High Prevalence of CV Events

Both LVH and Renal Damage

RenalDamage

51.4

LVH

58.9

No LVH and No Renal Damage

37.7

Pre

vale

nce

of

CV

Ev

en

t H

isto

ry (

%)

70.6

Cea-Calvo L, et al. Cardiovascular Diabetology. 2006;5:23.

N=2339. LVH=left ventricular hypertrophy.

Early glycemic control provides lasting protection: The legacy effect

10-year post-trial monitoring from 1997 to 2007 of UKPDS Study†

• Randomized intervention to achieve either intensive or conventional targets - stopped at the trial end (1997)• Differences in mean HbA1c between the two groups were lost by year 1 of post-trial follow-up. • Relative reductions in risk in patients who had been treated to intensive goals, compared with conventional targets,

persisted after 10 years

† Data from sulfonylurea–insulin group shown* P≤0.05; ** P≤0.01; *** P≤0.001; -25

-20

-15

-10

-5

0

Microvasculardisease

MyocardialInfraction

Any diabetes-related endpoint

Death fromany cause

Rel

ativ

e R

isk

Red

uct

ion

(%

)

Trial end (1997)

Post-trial follow up (2007)

*

***

**

***

***

*

The legacy effect – a reduction in complications persists 10 years after intensive therapy

1. UKPDS 33 Study Group. Lancet. 1998;352:837-853; 2. Holman RR, et al. N Engl J Med. 2008;359:1577-1589.3. Chalmers J and Cooper ME. N Engl J Med. 2008; 359: 1618–1620.

UKPDS – Significant Risk Reduction1

for T2DM Complications with each 1% Reduction in Mean HbA1c

-21-19-16-12-14

-43-37

StrokeMIPVD1Micro-vasculardisease

Heartfailure

Cataractextraction

Deathrelated todiabetes

Risk Reduction With 1% Decline in Updated HbA1c

P <.0001P =.035 P =.021 P <.0001P <.0001

1. Prospective observational analysis of UKPDS patients (n = 4585, incidence analysis; n = 3642, relative risk analysis). Median

10.0 years of follow up

Adapted from Stratton IM, et al. BMJ 2000;321:405–412